Sponsor or institution
Clinical trials and research at Hangzhou Sumgen Biotech Co., Ltd.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Hangzhou Sumgen Biotech Co., Ltd. that are recruiting, in China. By phase: Phase 2 (2), Phase 1/2 (1), Phase 3 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| SG301 SC Injection safety in adults with primary ITP | Phase 2 | Fuzhou, Fujian and 21 other locations | Recruiting | Jul 17, 2026 |
| See if SG2918 is safe for adults with relapsed/refractory multiple myeloma | Phase 1/2 | Zhengzhou, Henan and 3 other locations | Recruiting | Mar 6, 2026 |
| SG301 subcutaneous injection for people with active lupus | Phase 2 | Beijing, Beijing Municipality and 39 other locations | Recruiting | Mar 4, 2026 |
| Comparing SG301 with standard treatment for relapsed multiple myeloma | Phase 3 | Beijing, Beijing Municipality and 11 other locations | Recruiting | Jul 19, 2024 |
| SG1906 treatment for certain solid tumors | Phase 1 | Beijing, Beijing Municipality and 8 other locations | Recruiting | May 12, 2023 |
All recruiting trials (5)
-
SG301 SC Injection safety in adults with primary ITP
This Phase 2 study tests SG301 SC injection at two doses versus placebo in adults with primary immune thrombocytopenia to see if it is safe and helps raise platelet counts.
-
See if SG2918 is safe for adults with relapsed/refractory multiple myeloma
This study tests SG2918 in adults with relapsed or refractory multiple myeloma to see if it is safe and tolerable.
-
SG301 subcutaneous injection for people with active lupus
This study will test whether SG301, given as an under-the-skin injection, can help people with active, autoantibody-positive systemic lupus erythematosus who have not adequately responded to standard treatments.
-
Comparing SG301 with standard treatment for relapsed multiple myeloma
This study is testing if adding a new injection called SG301 to standard treatments can help people with relapsed multiple myeloma feel better and have better results.
-
SG1906 treatment for certain solid tumors
This study is testing a new treatment called SG1906 for people with certain hard-to-treat solid tumors to see if it is safe and effective.
Quick answers
How many clinical trials run by Hangzhou Sumgen Biotech Co., Ltd. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.